Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM LACTATE IN PLASTIC CONTAINER vs ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium lactate is converted to bicarbonate in the liver, providing an alkalizing effect to correct metabolic acidosis.
Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.
Treatment of metabolic acidosis,Correction of electrolyte disturbances
Fluid and electrolyte replacement in patients with normal or mildly depleted intravascular volume,Treatment and prevention of hypokalemia,Metabolic acidosis correction,Caloric supplementation when peripheral parenteral nutrition is indicated
Intravenous (IV) infusion: Initial dose 300-500 m L of 1/6 M (M/6) sodium lactate solution (167 m Eq/L of sodium and lactate) infused over 1-2 hours; subsequent doses based on serum bicarbonate levels and clinical response.
Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.
The terminal elimination half-life of lactate is approximately 5–10 minutes due to rapid hepatic metabolism; this short half-life allows quick correction of metabolic acidosis when administered intravenously.
Not applicable (dextrose and electrolytes are endogenous substances; distribution and elimination are rapid, with a functional half-life of minutes to hours depending on infusion rate and renal function).
Metabolized in the liver via lactate dehydrogenase and the Cori cycle to bicarbonate and glucose.
Dextrose is metabolized via glycolysis and the citric acid cycle. Acetate is metabolized primarily in the liver and muscle to bicarbonate. Gluconate is converted to glucose or metabolized via the pentose phosphate pathway.
Sodium lactate is metabolized to bicarbonate in the liver via the Cori cycle; less than 5% is excreted unchanged in urine under normal conditions. Biliary/fecal elimination is negligible.
Renal: 100% (as free water and electrolytes, not metabolized). Biliary/Fecal: negligible.
Minimal protein binding (<5%) as lactate is a small, water-soluble molecule; not significantly bound to plasma proteins.
Negligible (<5%) for dextrose and electrolytes; no specific binding proteins.
Volume of distribution approximates total body water (0.5–0.6 L/kg) because lactate distributes freely into the extracellular and intracellular spaces; this reflects its rapid equilibration.
Dextrose: ~0.2 L/kg (total body water); Electrolytes: ~0.4 L/kg (extracellular fluid). Clinical meaning: distributes throughout total body water.
Intravenous: 100% (administered directly into the bloodstream). Oral: Not clinically used; oral administration is not bioavailable as lactate is metabolized in the gut and liver first-pass.
Intravenous: 100%.
Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of fluid overload and hypernatremia; for GFR 30-59 m L/min, use with caution and reduce infusion rate by 50%.
Monitoring of electrolytes and volume status required; dosage adjustment not standardized; avoid in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to risk of hyperkalemia and fluid overload.
Child-Pugh Class A: No adjustment; Class B: Use with caution, reduce dose by 25%; Class C: Avoid use due to impaired lactate metabolism.
No specific adjustment recommended; monitor electrolytes and acid-base balance; caution in severe hepatic impairment due to altered fluid clearance.
Neonates and infants: 4.5 m L/kg of M/6 sodium lactate IV over 1 hour; children: 20-30 m L/kg of M/6 sodium lactate IV at a rate not exceeding 10 m L/kg/hour, titrated to monitoring of acid-base status.
Weight-based: 100-150 m L/kg/day for maintenance; adjust for ongoing losses; use with caution in neonates and children with renal impairment.
Elderly patients: Start at low end of dosing range, monitor for fluid overload, hypernatremia, and metabolic alkalosis; infusion rate not to exceed 100 m L/hour due to reduced cardiac and renal reserve.
Consider reduced starting rates due to decreased renal function and increased risk of fluid overload; monitor electrolytes and volume status closely; adjust rate based on comorbidities.
None
NOT FOR USE IN HYPERLACTATEMIA, SEVERE METABOLIC ALKALOSIS, OR SEVERE HEPATIC FAILURE; CONTAINS ALUMINUM WHICH MAY BE TOXIC WITH PROLONGED USE IN RENAL IMPAIRMENT; ADDITIVES MAY BE INCOMPATIBLE, CONSULT PHARMACIST.
Use with caution in patients with lactic acidosis if etiology is not correctable,Monitor serum electrolytes, acid-base status, and fluid balance,Risk of fluid overload in patients with heart failure or renal impairment
Monitor serum electrolytes, fluid balance, and blood glucose. Use with caution in patients with heart failure, renal impairment, hepatic disease, or hyperglycemia. Hypersensitivity reactions may occur. Avoid rapid or large-volume infusion in patients with impaired glucose tolerance.
Severe metabolic alkalosis,Hypernatremia (if sodium-containing),Lactic acidosis not due to correctable causes
Hypernatremia, hyperkalemia, hypermagnesemia, hypercalcemia, hyperlactatemia, severe metabolic alkalosis, severe hepatic failure, hyperglycemic states, anuria, or known hypersensitivity to any component.
No known dietary restrictions or food interactions. However, monitor nutritional intake in patients receiving long-term therapy, as electrolyte imbalances may require dietary adjustments.
No known food interactions. However, patients with diabetes should be aware of dextrose content which affects blood glucose. Dietary potassium or magnesium restriction may be necessary if electrolyte imbalances occur.
Sodium lactate is used as an intravenous electrolyte replenisher and alkalizing agent. Data on teratogenic risk are limited. In animal studies, sodium lactate did not show fetal harm at doses within clinical range. However, no well-controlled human studies exist. The risk is considered low but cannot be excluded. Use in pregnancy only if clearly needed.
No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in uncontrolled maternal diabetes may cause fetal malformations. Use cautiously in gestational diabetes.
Sodium lactate is a normal constituent of plasma and breast milk. Exogenous administration does not significantly alter milk composition. M/P ratio is not established but expected to be near 1. It is considered compatible with breastfeeding.
Dextrose and electrolytes pass into breast milk but are normal milk constituents. No adverse effects expected in term infants. M/P ratio not determined as these are endogenous substances. Consider maternal fluid/electrolyte status.
No specific dose adjustments required for pregnancy. However, monitor for fluid overload and electrolyte disturbances, especially in preeclampsia or renal impairment.
No specific dose adjustment needed. Monitor for volume expansion in pregnancy (increased intravascular space). Adjust rate based on maternal glucose, electrolytes, and clinical response. Avoid excess dextrose in gestational diabetes.
Sodium lactate in plastic container is used as a source of bicarbonate precursor for metabolic acidosis. It is contraindicated in lactic acidosis because it requires hepatic metabolism to bicarbonate. Monitor serum lactate and p H closely during infusion. The plastic container may leach DEHP; use with caution in neonates and pregnant women.
ISOLYTE E W/ DEXTROSE 5% is an isotonic, balanced electrolyte solution with 5% dextrose for parenteral replacement of fluid and electrolytes. It contains potassium, magnesium, and acetate (bicarbonate precursor). Avoid in patients with hyperkalemia, hypermagnesemia, or metabolic alkalosis. Monitor serum electrolytes, glucose, and renal function. Use with caution in heart failure, renal impairment, and patients at risk for fluid overload. Do not administer if cloudy or precipitate present. Discard any unused portion.
This medication is given intravenously to correct acid buildup in the blood.,Tell your healthcare provider if you have liver disease, as it may affect how this drug works.,Inform your doctor if you are pregnant or breastfeeding.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing.,Do not suddenly stop treatment without consulting your doctor.
This solution provides fluids, sugar, and electrolytes to correct imbalances.,Your healthcare team will monitor your blood sugar and electrolyte levels during treatment.,Report any symptoms like swelling, shortness of breath, or changes in urination.,This medication is given only in a hospital or clinic setting by a healthcare professional.,Tell your doctor if you have any allergies, especially to corn (dextrose source).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM LACTATE IN PLASTIC CONTAINER vs ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
SODIUM LACTATE IN PLASTIC CONTAINER is a Electrolyte Solution that works by Sodium lactate is converted to bicarbonate in the liver, providing an alkalizing effect to correct metabolic acidosis.. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM LACTATE IN PLASTIC CONTAINER and ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM LACTATE IN PLASTIC CONTAINER is: Intravenous (IV) infusion: Initial dose 300-500 m L of 1/6 M (M/6) sodium lactate solution (167 m Eq/L of sodium and lactate) infused over 1-2 hours; subsequent doses based on serum bicarbonate levels and clinical response.. The standard adult dose of ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM LACTATE IN PLASTIC CONTAINER and ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM LACTATE IN PLASTIC CONTAINER is classified as Category C. Sodium lactate is used as an intravenous electrolyte replenisher and alkalizing agent. Data on teratogenic risk are limited. In animal studies, sodium lactate did not show fetal ha. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in unco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.